Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

A. Prahallad · SciRah

Researcher profile · Semantic Scholar

A. Prahallad

Share profile

A. Prahallad — researcher profile on SciRah

h-index: 15
Works: 34
Citations: 4,329

Most-cited papers

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
A. Prahallad, Chong Sun, Si-Dong Huang, F. Di Nicolantonio +5 more
2012Nature1,962 citations Open access
Semantic Scholar
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
Chong Sun, Liqin Wang, Si-Dong Huang, G. Heynen +21 more
2014Nature827 citations Open access
Semantic Scholar
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Si-Dong Huang, M. Hölzel, T. Knijnenburg, A. Schlicker +17 more
2012Cell419 citations Open access
Semantic Scholar
Intrinsic resistance to MEK inhibition in KRAS mutant lung and colon cancer through transcriptional induction of ERBB3.
Chong Sun, S. Hobor, A. Bertotti, D. Zecchin +17 more
2014Cell Reports305 citations Open access
Semantic Scholar
SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo
S. Mainardi, A. Mulero-Sánchez, A. Prahallad, G. Germano +10 more
2018Nature Medicine297 citations Open access
Semantic Scholar
PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs.
A. Prahallad, G. Heynen, G. Germano, S. Willems +8 more
2014Cell Reports168 citations Open access
Semantic Scholar
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity
P. K. Bajpe, A. Prahallad, Hugo M. Horlings, I. Nagtegaal +2 more
2014Oncogene52 citations Open access
Semantic Scholar
Opportunities and challenges provided by crosstalk between signalling pathways in cancer
A. Prahallad, R. Bernards
2016Oncogene44 citations
Semantic Scholar
A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAFV600E colorectal tumors
A. Ruiz-Sáenz, C. Atreya, Chang-Jun Wang, B. Pan +21 more
2023Nature Cancer42 citations Open access
Semantic Scholar
Mapping phospho-catalytic dependencies of therapy-resistant tumours reveals actionable vulnerabilities
Jean-Philippe Coppé, M. Mori, B. Pan, C. Yau +16 more
2019Nature Cell Biology39 citations Open access
Semantic Scholar
Modelling Signalling Networks from Perturbation Data
Mathurin Dorel, B. Klinger, Torsten Gross, A. Sieber +4 more
2018bioRxiv27 citations Open access
Semantic Scholar
Genetic heterogeneity and clonal evolution during metastasis in breast cancer patient-derived tumor xenograft models
K. Sprouffske, G. Kerr, Cheng Li, A. Prahallad +9 more
2020Computational and Structural Biotechnology Journal26 citations Open access
Semantic Scholar
Ruxolitinib for pediatric patients with treatment-naïve and steroid-refractory acute graft-versus-host disease (REACH4).
F. Locatelli, H. Kang, B. Bruno, V. Gandemer +11 more
2024Blood24 citations Open access
Semantic Scholar
CRISPR Screening Identifies Mechanisms of Resistance to KRASG12C and SHP2 Inhibitor Combinations in Non–Small Cell Lung Cancer
A. Prahallad, Andreas Weiss, Hans Voshol, G. Kerr +18 more
2023Cancer Research24 citations Open access
Semantic Scholar
Prognostic value of blood biomarkers in steroid-refractory or steroid-dependent acute graft-versus-host disease: a REACH2 analysis
G. Socié, D. Niederwieser, N. von Bubnoff, M. Mohty +6 more
2023Blood16 citations Open access
Semantic Scholar
A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells*
Anna Ressa, Evert Bosdriesz, J. de Ligt, S. Mainardi +11 more
2017Molecular & Cellular Proteomics15 citations Open access
Semantic Scholar
Ruxolitinib in Pediatric Patients with Treatment-Naïve or Steroid-Refractory Acute Graft-Versus-Host Disease: Primary Findings from the Phase I/II REACH4 Study
F. Locatelli, H. Kang, B. Bruno, V. Gandemer +11 more
2022Blood10 citations
Semantic Scholar
Comparative Network Reconstruction using mixed integer programming
Evert Bosdriesz, A. Prahallad, B. Klinger, A. Sieber +4 more
2018bioRxiv10 citations Open access
Semantic Scholar
Preclinical studies on the use of a P-selectin blocking monoclonal antibody to halt progression of myelofibrosis in the Gata1low mouse model
P. Verachi, F. Gobbo, F. Martelli, M. Falchi +8 more
2022Experimental Hematology9 citations Open access
Semantic Scholar
Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models
S. Brachmann, A. Weiss, Daniel A. Guthy, Kim Beyer +27 more
2021Poster Presentations - Proffered Abstracts7 citations
Semantic Scholar
Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
F. Heidel, A. Perkins, A. Reiter, C. Crodel +18 more
2022Blood4 citations Open access
Semantic Scholar
Biomarker Analysis in Patients (pts) with Steroid-Refractory Acute Graft-Vs-Host Disease (aGVHD) Treated with Ruxolitinib (RUX) or Best Available Therapy (BAT) in the Randomized, Phase 3 REACH2 Study
G. Socié, D. Niederwieser, N. von Bubnoff, M. Mohty +16 more
20204 citations Open access
Semantic Scholar
ADORE: an open platform study of ruxolitinib in combination with other novel therapies in patients with myelofibrosis
David M. Ross, F. Heidel, A. Perkins, Andreas Reiter +19 more
2025Blood Advances2 citations Open access
Semantic Scholar
A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAFV600E colorectal tumors
A. Ruiz-Sáenz, C. Atreya, Chang-Jun Wang, B. Pan +21 more
2022bioRxiv0 citations Open access
Semantic Scholar
Abstract B023: A reversible SRC-relayed COX2-inflammatory program drives therapeutic resistance in BRAF(V600E) colorectal tumors
C. Atreya, A. Ruiz-Sáenz, Chang-Jun Wang, B. Pan +11 more
2019Genomics, Proteomics, and Target Discovery0 citations
Semantic Scholar
Deciphering mechanisms of response and resistance in large-scale mouse cancer screens.
A. Prahallad, M. Jensen, Emilie A. Chapeau
2019Current Opinion in Genetics and Development0 citations
Semantic Scholar
Identifying rational combination therapies for colorectal cancer using functional genetics
A. Prahallad
20150 citations
Semantic Scholar
Compositions pour le traitement du cancer
R. Bernards, S. van Wageningen, Gustaaf Josephus Johannes Eugene Heynen, A. Prahallad +1 more
20150 citations
Semantic Scholar
Abstract 3697: SIRT2 is a modulator of response to targeted therapies through regulation of MEK kinase activity
P. K. Bajpe, A. Prahallad, Hugo M. Horlings, I. Nagtegaal +2 more
20140 citations
Semantic Scholar
148 RAS synthetic lethal interactions from yeast to human cells
S. van Wageningen, A. Prahallad, Gustaaf Josephus Johannes Eugene Heynen, R. Rothstein +1 more
20140 citations
Semantic Scholar
566 Mechanisms of Resistance to MEK Inhibitor AZ6244 in KRAS Mutant Metastatic Colorectal Cancer
Valentina Gambino, Chong Sun, A. Prahallad, Anna Tzani +3 more
20120 citations
Semantic Scholar
159 Loss of SIRT2 Confers Resistance to Targeted Therapies
P. Bajpe, A. Prahallad, P. Halonen, Hugo M. Horlings +3 more
20120 citations
Semantic Scholar
89 Interrogating the Genome to Find Mechanisms of Drug Resistance in Cancer
R. Bernards, S. Huang, A. Prahallad, C. Sun
20120 citations
Semantic Scholar
Oncogene collaboration revisited from a historical perspective
A. Prahallad
20100 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

R. Bernards×17
Invite
R. Bernards — researcher profile on SciRah
R. Beijersbergen×7
Invite
R. Beijersbergen — researcher profile on SciRah
Chong Sun×5
Invite
Chong Sun — researcher profile on SciRah
A. Bardelli×5
Invite
A. Bardelli — researcher profile on SciRah

×4

Invite

Si-Dong Huang — researcher profile on SciRah

F. Di Nicolantonio×4

Invite

F. Di Nicolantonio — researcher profile on SciRah

Invite

C. Lieftink — researcher profile on SciRah

Wipawadee Grernrum×4

Invite

Wipawadee Grernrum — researcher profile on SciRah

A. Ruiz-Sáenz×4

Invite

A. Ruiz-Sáenz — researcher profile on SciRah

Chang-Jun Wang×4

Invite

Chang-Jun Wang — researcher profile on SciRah

Invite

B. Pan — researcher profile on SciRah

Invite

C. Dreyer — researcher profile on SciRah